Download pdf
The application of metformin in the treatment of diabetes
- 1 The Second Clinical Medical College, Wenzhou Medical University, Wenzhou, China
* Author to whom correspondence should be addressed.
Abstract
In recent years, the prevalence of diabetes (TDM) has increased. Metformin, a quintessential hypoglycemic agent, exhibits substantial hypoglycemia effects and possesses various clinical applications. This article reviews the application of metformin in the treatment of diabetes, analyzing its mechanism of action, clinical efficacy, and safety. Studies have found that metformin performs outstandingly in the intervention of pre-diabetes, cardiovascular protection, and weight management, and the combined treatment effects are significant. Its safety and cost-effectiveness make it an irreplaceable position in the treatment of diabetes. Frequent adverse effects of metformin encompass gastrointestinal distress and vitamin B12 deficiency resulting from prolonged usage. The future development of metformin will focus on precision and long-acting effects, optimizing treatment outcomes through targeted and sustained-release technologies, while meeting individual medication needs.
Keywords
metformin, type 2 diabetes mellitus, efficacy evaluation, drug safety
[1]. IDF. (2021). 9th Edition: Diabetes Atlas. International Diabetes Federation.
[2]. American Diabetes Association. (2020). Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43(Suppl 1), S98-S110.
[3]. Sanchez-Rangel, E. (2021). Metformin: Clinical Use in Type 2 Diabetes. Endocrinol Metab Clin North Am, 50(3), 463-476.
[4]. FDA. (2020). Metformin Hydrochloride Drug Information. U.S. Food and Drug Administration.
[5]. Foretz, M. (2023). Metformin: Update on Mechanisms of Action and Therapeutic Strategies. Trends Endocrinol Metab, 34(8), 460-474.
[6]. Foretz, M. (2019). Metformin: from mechanisms of action to therapies. Cell Metabolism, 30(1), 24-35.
[7]. Madiraju, A. K. (2018). Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature, 560(7719), 471-475.
[8]. de la Cuesta-Zuluaga, J. (2019). Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care, 42(5), 856-866.
[9]. Ortega, F. J. (2020). Targeting the circulating microRNA signature of obesity. Clinical Chemistry, 66(1), 158-167.
[10]. Pollak, M. (2020). The effects of metformin on gut microbiota and the immune system as research frontiers. Diabetologia, 63(9), 1666-1678.
[11]. Zhang, X. (2020). Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature Communications, 11(1), 1-12.
[12]. Wu, Y. (2021). Metformin promotes glucose uptake in skeletal muscle through AMPK-mediated activation of Rab GTPases. Journal of Biological Chemistry, 296, 100-110.
[13]. Lee, J. H. (2023). Impact of metformin on metabolic syndrome in type 2 diabetes patients. Journal of the American Medical Association (JAMA), 329(15), 1456-1464.
[14]. Tseng, C. H. (2018). Metformin and the risk of hypoglycemia in type 2 diabetes: a cohort study. Diabetes Care, 41(5), 950-955.
Cite this article
Lei,R. (2025). The application of metformin in the treatment of diabetes. Journal of Clinical Technology and Theory,3(1),15-18.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Journal：Journal of Clinical Technology and Theory
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).